These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
336 related articles for article (PubMed ID: 19346236)
1. Systems biology of autosomal dominant polycystic kidney disease (ADPKD): computational identification of gene expression pathways and integrated regulatory networks. Song X; Di Giovanni V; He N; Wang K; Ingram A; Rosenblum ND; Pei Y Hum Mol Genet; 2009 Jul; 18(13):2328-43. PubMed ID: 19346236 [TBL] [Abstract][Full Text] [Related]
2. Toxic tubular injury in kidneys from Pkd1-deletion mice accelerates cystogenesis accompanied by dysregulated planar cell polarity and canonical Wnt signaling pathways. Happé H; Leonhard WN; van der Wal A; van de Water B; Lantinga-van Leeuwen IS; Breuning MH; de Heer E; Peters DJ Hum Mol Genet; 2009 Jul; 18(14):2532-42. PubMed ID: 19401297 [TBL] [Abstract][Full Text] [Related]
3. Curcumin inhibits cystogenesis by simultaneous interference of multiple signaling pathways: in vivo evidence from a Pkd1-deletion model. Leonhard WN; van der Wal A; Novalic Z; Kunnen SJ; Gansevoort RT; Breuning MH; de Heer E; Peters DJ Am J Physiol Renal Physiol; 2011 May; 300(5):F1193-202. PubMed ID: 21345977 [TBL] [Abstract][Full Text] [Related]
8. Dysregulation of cellular proliferation and apoptosis mediates human autosomal dominant polycystic kidney disease (ADPKD). Lanoix J; D'Agati V; Szabolcs M; Trudel M Oncogene; 1996 Sep; 13(6):1153-60. PubMed ID: 8808689 [TBL] [Abstract][Full Text] [Related]
9. Altered Hippo signalling in polycystic kidney disease. Happé H; van der Wal AM; Leonhard WN; Kunnen SJ; Breuning MH; de Heer E; Peters DJ J Pathol; 2011 May; 224(1):133-42. PubMed ID: 21381034 [TBL] [Abstract][Full Text] [Related]
10. Molecular signature and therapeutic perspective of the epithelial-to-mesenchymal transitions in epithelial cancers. Sabbah M; Emami S; Redeuilh G; Julien S; Prévost G; Zimber A; Ouelaa R; Bracke M; De Wever O; Gespach C Drug Resist Updat; 2008; 11(4-5):123-51. PubMed ID: 18718806 [TBL] [Abstract][Full Text] [Related]
11. Autocrine, endocrine and paracrine regulation of growth abnormalities in autosomal dominant polycystic kidney disease. Wilson PD; Du J; Norman JT Eur J Cell Biol; 1993 Jun; 61(1):131-8. PubMed ID: 8223698 [TBL] [Abstract][Full Text] [Related]
12. Aberrant expression of SPARC and its impact on proliferation and apoptosis in ADPKD cyst-lining epithelia. Wang W; Mei C; Tang B; Zhao H; Xu C; Li Z; Shen X; Fu W; Dai B Nephrol Dial Transplant; 2006 May; 21(5):1278-88. PubMed ID: 16421164 [TBL] [Abstract][Full Text] [Related]
13. Pkd1 regulates immortalized proliferation of renal tubular epithelial cells through p53 induction and JNK activation. Nishio S; Hatano M; Nagata M; Horie S; Koike T; Tokuhisa T; Mochizuki T J Clin Invest; 2005 Apr; 115(4):910-8. PubMed ID: 15761494 [TBL] [Abstract][Full Text] [Related]
14. Cyst number but not the rate of cystic growth is associated with the mutated gene in autosomal dominant polycystic kidney disease. Harris PC; Bae KT; Rossetti S; Torres VE; Grantham JJ; Chapman AB; Guay-Woodford LM; King BF; Wetzel LH; Baumgarten DA; Kenney PJ; Consugar M; Klahr S; Bennett WM; Meyers CM; Zhang QJ; Thompson PA; Zhu F; Miller JP J Am Soc Nephrol; 2006 Nov; 17(11):3013-9. PubMed ID: 17035604 [TBL] [Abstract][Full Text] [Related]
15. Increased activity of activator protein-1 transcription factor components ATF2, c-Jun, and c-Fos in human and mouse autosomal dominant polycystic kidney disease. Le NH; van der Wal A; van der Bent P; Lantinga-van Leeuwen IS; Breuning MH; van Dam H; de Heer E; Peters DJ J Am Soc Nephrol; 2005 Sep; 16(9):2724-31. PubMed ID: 16049073 [TBL] [Abstract][Full Text] [Related]
16. Activation of the AKT/mTOR pathway in autosomal recessive polycystic kidney disease (ARPKD). Fischer DC; Jacoby U; Pape L; Ward CJ; Kuwertz-Broeking E; Renken C; Nizze H; Querfeld U; Rudolph B; Mueller-Wiefel DE; Bergmann C; Haffner D Nephrol Dial Transplant; 2009 Jun; 24(6):1819-27. PubMed ID: 19176689 [TBL] [Abstract][Full Text] [Related]
17. Influence of VEGF polymorphism on progression of autosomal dominant polycystic kidney disease. Reiterová J; Obeidová H; Lenícek M; Stekrová J; Merta M; Maixnerová D; Vítek L; Viklický O; Tesar V Kidney Blood Press Res; 2008; 31(6):398-403. PubMed ID: 19060482 [TBL] [Abstract][Full Text] [Related]
18. Characterisation of transcription factor profiles in polycystic kidney disease (PKD): identification and validation of STAT3 and RUNX1 in the injury/repair response and PKD progression. Formica C; Malas T; Balog J; Verburg L; 't Hoen PAC; Peters DJM J Mol Med (Berl); 2019 Dec; 97(12):1643-1656. PubMed ID: 31773180 [TBL] [Abstract][Full Text] [Related]
19. [Heterozygosity loss and somatic mutations in type I and II dominant autosomal renal polycystic kidney disease: evidence of a recessive mechanism at a cell level in cystogenesis]. Pérez-Oller L; Torra R; Badenas C; San Millán JL; Darnell A Nefrologia; 2000; 20(2):130-8. PubMed ID: 10853193 [TBL] [Abstract][Full Text] [Related]